Spring Bank is developing a pipeline of products representing a new class of pharmaceuticals we call small molecule nucleic acid hybrids. “SMNH” with a wide range of applications and multi-billion dollar market potential.

Spring Bank is pursuing the development of novel therapeutics for the treatment of a range of diseases including viral diseases, autoimmune diseases and cancer.

SMNH technology produces a class of drugs combining the specificity and selectivity advantages of antisense and RNAi with the favorable drug like qualities of traditional small molecules.